Neogenomics (NEO) Shares Outstanding (2010 - 2026)

Neogenomics (NEO) has 17 years of Shares Outstanding (Entity) data on file, last reported at $130.3 million in Q2 2026.

• Quarterly Shares Outstanding (Entity) rose 1.26% year-over-year to $130.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $130.3 million (up 1.26% YoY) and the FY2025 annual result came in at $129.0 million, up 0.66% from the prior year.
• Shares Outstanding (Entity) steadied at $130.3 million in Q2 2026, from $129.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $130.3 million in Q2 2026 to a low of $124.7 million in Q1 2022.
• A 5-year average of $127.7 million and a median of $127.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) rose 6.48% — and 2024, when it climbed 0.18%.
• Tracing NEO's Shares Outstanding (Entity) over 5 years: stood at $126.9 million in 2022, then climbed by 0.36% to $127.4 million in 2023, then gained by 0.61% to $128.1 million in 2024, then gained by 0.66% to $129.0 million in 2025, then grew by 1.02% to $130.3 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $130.3 million (Q2 2026), $129.7 million (Q1 2026), and $129.0 million (Q4 2025), per Business Quant data.